Showing 621-630 of 1600 results for "".
- Resident of Distinction Award Celebrates 10th Anniversary at 2020 Caribbean Dermatology Symposiumhttps://practicaldermatology.com/news/resident-of-distinction-award-celebrates-10th-anniversary-at-2020-caribbean-dermatology-symposium/2460276/As part of the dermMentors Resident of Distinction Award, Beiersdorf Inc. sponsored five top dermatology residents to attend the 2020 Caribbean Dermatology Symposium, held in Paradise Island, Bahamas, from Jan. 21-25, 2020.
- BioPharmX Corporation and Timber Pharmaceuticals LLC Announce Mergerhttps://practicaldermatology.com/news/biopharmx-corporation-and-timber-pharmaceuticals-llc-announce-merger/2460267/BioPharmX Corporation and Timber Pharmaceuticals LLC have entered into a definitive merger agreement. Under the terms of the merger agreement, subject to the approval of BioPharmX's stockholders and Timber's members, a wholly-owned subsidiary of BioPharmX will be merged wit
- Highlights from Day 3 at DERM2019: Hyperhidrosis, Bug Bites, Sunscreen, and Morehttps://practicaldermatology.com/news/highlights-from-day-3-at-derm2019-hyperhidrosis-bug-bites-sunscreen-and-more/2460101/As the nation observed the 50th anniversary of the Apollo 11 lunar landing, the day the famous quote from astronaut Neil Armstrong was spoken “That’s one small step for a man, one giant leap for mankind," DERM2019 organziers say the shot for the stars with their faculty were not
- LEO Pharma Completes Acquisition of Bayer’s Prescription Dermatology Businesshttps://practicaldermatology.com/news/leo-pharma-completes-acquisition-of-bayers-prescription-dermatology-business/2460086/LEO Pharma and Bayer announced the achievement of the relevant closing conditions to allow the transfer of Bayer’s global prescription dermatology business to LEO Pharma. The companies first announced the proposed transaction on July 31, 2018 and completed the first step of the acquisition
- Phase 3b/4 Study ANSWERs Rosacea Therapy Questionshttps://practicaldermatology.com/news/phase-3b4-study-answers-rosacea-therapy-questions/2460082/Results of the phase 3b/4 ANSWER study, recently published onlinein the Journal of the American Academy of Dermatology, show that concomitant use of Oracea Capsules and Soolantra Cream provided significan
- L'Oréal Partners with uBiome to Advance New Research on the Skin's Microbiomehttps://practicaldermatology.com/news/loral-partners-with-ubiome-to-advance-new-research-on-the-skins-microbiome/2459980/L'Oréal’s tech Incubator is joining forces with uBiome, a Silicon Valley-based microbiome research venture. The partnership was announced at L'Oréal's "Know Your Sk
- Cutera to Unveil excel V+ Next Generation Laser Platform at AAD Annual Meetinghttps://practicaldermatology.com/news/cutera-to-unveil-excel-v-next-generation-laser-platform-at-aad-annual-meeting/2459888/Cutera, Inc. has launched its excel V+ laser platform, which the company describes as a technological advancement that includes 50 percent more power and treatment speed, optimized delivery systems and parameters for treating vascular lesions and pigmentation concerns. Cutera will unveil the exce
- Leadership Changes Announced for Cuterahttps://practicaldermatology.com/news/leadership-changes-announced-for-cutera/2459944/Cutera, Inc.'s James Reinstein resigned as President, Chief Executive Officer, and member of its Board of Directors, effective immediately. The Board has appointed Cutera’s Chief Operating Officer, Jason Richey, as Interim CEO. J. Daniel Plants, Chairman of Cutera, said: &
- Sinclair Pharma Announces Leadership Changeshttps://practicaldermatology.com/news/sinclair-pharma-announces-leadership-changes/2457491/Sinclair Pharma Limited reported that effective at the end of the year, Doug Abel has resigned his position as Head of North America and President of Silhouette Lift, Inc., to lead a new aesthetic venture and has licensed the US sales and marketing rights to the Refine Support System from Sinclai
- Encore Dermatology Announces Phase 2 Safety Data for Impoyzhttps://practicaldermatology.com/news/encore-dermatology-announces-phase-2-safety-data-for-impoyz/2457496/A Phase 2, open-label study published in SKIN The Journal of Cutaneous Medicine, found that subjects treated with Impoyz (clobetasol propionate) Cream, 0.025% showed significantly lower mean post-treatment clobetasol propionate plasma concentrations versus the subjects treated with Temov